MDR & XDR TB

Synergists for existing drugs

A method and composition for treatment of tuberculosis including MDR & XDR varieties and latent tuberculosis has been disclosed in a patent application filed by Pfizer Inc.[1]  In the claimed composition, an effective amount of (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide  or a pharmaceutically acceptable salt thereof is used along with at least two drugs conventionally used for treatment of TB.  A medicament for treating TB after a patient has undergone initial treatment is also claimed wherein abovementioned acetamide is used in combination with at least one anti-tuberculin agent.  The invention prevents relapse of infection after completion of the treatment.  

A patent application[2] has been filed by Vertex Pharmaceuticals Inc., USA, wherein it is claimed that a composition containing a compound “Timcodar” is useful for the treatment of patients with mycobacterial infections, such as Mycobacterium tuberculosis, esp. in multidrug resistant diseases.  Timcodar alone had no significant effect on the in vitro growth of M. tuberculosis, Timcodar in combination with rifampicin potentiated the in vivo antibacterial activity of rifampicin by one log CFU in mice.  While Timcodar did enhance isoniazid activity in vivo, it did not do so to the same extent as rifampicin.  


Key Words:  multidrug resistant tuberculosis, extensively drug resistant tuberculosis, multidrug resistant TB,  extensively drug resistant TB, MDR TB, XDR TB, mycobacterium tuberculosis, mycobacterial infection, literature, research, publications, patents.

---

[1] Patent application No.US2011190199.

[2] Compositions of N-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]]propanamide for treatment of mycobacterial infections. Vertex Pharmaceuticals Inc., USA).  PCT Int. Appl. WO 2011031926 A1 17 Mar 2011, 35pp.